Drug Patents Expiring in 2042
1. Bortezomib patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752164 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(18 years from now) | |
| US11679119 | MAIA PHARMS INC | Bortezomib compositions |
Sep, 2042
(18 years from now) | |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Treatment of adult patients with multiple myeloma
Dosage: SOLUTION;INTRAVENOUS
BORTEZOMIB family patents
2. Defencath patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11738120 | CORMEDIX | Synthesis of taurolidine, purity profiles and polymorphs |
Apr, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Generating Antibiotic Incentives Now(GAIN) | Nov 15, 2033 |
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2028 |
Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient
NCE-1 date: 15 November, 2032
Market Authorisation Date: 15 November, 2023
Treatment: NA
Dosage: SOLUTION;N/A
DEFENCATH family patents
3. Galafold patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11833164 | AMICUS THERAP US | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
Jan, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE;ORAL
GALAFOLD family patents
4. Lumryz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11583510 | AVADEL CNS | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Feb, 2042
(17 years from now) | |
| US11779557 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Mar, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-431) | May 01, 2030 |
| New Product(NP) | May 01, 2026 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 01 May, 2023
Treatment: Treatment of narcolepsy, cataplexy or excessive daytime sleepiness using a once-nightly gamma-hydroxybutyrate formulation; Treatment of cataplexy or excessive daytime sleepiness in patients with narco...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
LUMRYZ family patents
5. Ogsiveo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11612588 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Jul, 2042
(18 years from now) | |
| US11504354 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Jul, 2042
(18 years from now) | |
| US11807611 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Sep, 2042
(18 years from now) | |
| US11844780 | SPRINGWORKS | Chlorinated tetralin compounds and pharmaceutical compositions |
Sep, 2042
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-452) | Nov 27, 2030 |
| New Chemical Entity Exclusivity(NCE) | Nov 27, 2028 |
Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient
NCE-1 date: 28 November, 2027
Market Authorisation Date: 27 November, 2023
Treatment: Treatment of adult patients with progressing desmoid tumors
Dosage: TABLET;ORAL
OGSIVEO family patents
6. Qinlock patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11779572 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Oct, 2042
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
| Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 15 May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of gastrointestinal stromal tumors in patients having pre-existing severe hepatic impairment and suffering from an adverse event while being administered ripretinib daily
Dosage: TABLET;ORAL
QINLOCK family patents
7. Sezaby patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857683 | SUN PHARM INDS INC | Stabilization of phenobarbital sodium for injection |
Apr, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-414) | Nov 17, 2029 |
Drugs and Companies using PHENOBARBITAL SODIUM ingredient
Market Authorisation Date: 17 November, 2022
Treatment: Method of treating neonatal seizures
Dosage: POWDER;INTRAVENOUS
SEZABY family patents
8. Sunosi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11771667 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US11771666 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US11793776 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| US11779554 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: Treatment of excessive daytime sleepiness in a breast-feeding patient while reducing infant exposure to solriamfetol
Dosage: TABLET;ORAL
SUNOSI family patents
9. Tyvaso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11826327 | UNITED THERAP | Treatment for interstitial lung disease |
Jan, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-856) | Mar 31, 2024 |
| M(M-145) | May 20, 2017 |
| Orphan Drug Exclusivity(ODE) | Jul 30, 2016 |
| New Dosage Form(NDF) | Jul 30, 2012 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 30 July, 2009
Treatment: Method of treating pulmonary hypertension associated with interstitial lung disease by administering treprostinil or a salt thereof by inhalation using a device
Dosage: SOLUTION;INHALATION
TYVASO family patents
10. Tyvaso Dpi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11826327 | UNITED THERAP | Treatment for interstitial lung disease |
Jan, 2042
(17 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: Method of treating pulmonary hypertension associated with interstitial lung disease by administering treprostinil or a salt thereof by inhalation using a device
Dosage: POWDER;INHALATION
TYVASO DPI family patents
11. Vivimusta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11844784 | SLAYBACK PHARMA LLC | Stable pharmaceutical compositions of bendamustine |
Jul, 2042
(18 years from now) | |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
VIVIMUSTA family patents
12. Xelstrym patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11559501 | NOVEN PHARMS INC | Transdermal amphetamine compositions with low levels of carbamate |
Jan, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2025 |
Drugs and Companies using DEXTROAMPHETAMINE ingredient
Market Authorisation Date: 22 March, 2022
Treatment: NA
Dosage: SYSTEM;TRANSDERMAL
XELSTRYM family patents